The CSL Limited (ASX: CSL) share price rose by almost 7% today after it reported its FY19 result.

CSL Limited (ASX: CSL) is Australia’s largest (and some might say best) healthcare company, specialising in biopharmaceuticals. Founded in the late 1900s as the Commonwealth Serum Laboratories, CSL was sold by the Australian Government to Australian investors via the share market in 1994 at $2.30 per share, at which time it doubled its size through an international acquisition. Today, CSL is a global leader in blood plasma vaccines (think: the flu) and antivenoms, providing relief for potentially life-threatening medical conditions.

Here’s What Happened

Investors were very pleased to learn that CSL provided net profit guidance of US$2.05 billion to US$2.11 billion in constant currency terms, which would be growth of 7% to 10%. This includes the one-off financial headwind of transitioning to a new model of direct distribution in China.

I think the profit growth would be impressive considering the hit to profit that CSL is expecting in FY20.

In FY19, CSL reported that its net profit after tax (NPAT) increased by 11% to US$1.92 billion for FY19, it rose 17% in constant currency terms. Revenue growth came in at 11%.

The CSL Board declared a final dividend of US$1 per share, bringing the total full year dividend to US$1.85 per share, which was an increase of 8%. In Australian dollar terms the full year dividend is $2.68, an increase of 18%.

It was a solid result and it’s no wonder that investors piled in with the healthcare giant predicting further growth in the near future.

After searching through a market with over 2,000 shares, our lead expert investment analyst has narrowed it down to just 2 of his favourite rapid-growth shares in a FREE report to Rask Media readers.

Over the past five years, these two shares have gone from being 'tiny caps' to being serious contenders for the ASX 200.

Idea #1 is taking on the world, starting with the huge USA market. In a just a few short years the company has snatched market share away from rivals and is on its way to being the market leader.

Idea #2 uses a 'printer and cartridge' type model to get large and established customers: a) using their healthcare industry-leading product, b) paying for it again and again and again... so it's little wonder this company is tipped to grow at a rapid pace in 2019.

Access the free report by clicking here now. Absolutely no credit card or payment details required.



Disclaimer: Any information contained in this article is limited to general financial/investment advice only. The information has not taken into account your specific needs, goals or objectives, so please consider consulting a licenced and trusted adviser before acting on the information. Please read The Rask Group’s Financial Services Guide (FSG) for more information. This article is authorised by Owen Raszkiewicz of The Rask Group, which is a corporate authorised representative No. 1264179 of Strawman Pty Ltd (ACN: 610 908 211) (AFSL: 501 223).

At the time of publishing, Jaz does not have a financial interest in any of the companies mentioned.